Who is sponsoring NCT01605201?

NCT01605201 is sponsored by University Hospital, Basel, Switzerland.

What drugs are being tested in NCT01605201?

Interventions in NCT01605201: Tissue engineered cartilage graft.

What condition does NCT01605201 study?

NCT01605201 studies Cartilage Lesion, Degenerative Lesion of Articular Cartilage of Knee.

Is NCT01605201 still recruiting?

NCT01605201 is currently completed. Last updated 27 August 2018.

Last reviewed 2018-08-27 · How we verify

NCT01605201: Nose2Knee

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tissue Engineered Nasal Cartilage for Regeneration of Articular Cartilage

Completed Phase 1 Last updated 27 August 2018

What this trial tests

Phase 1 trial testing Tissue engineered cartilage graft in Cartilage Lesion in 18 participants. Completed in 15 August 2018.

Timeline

29 August 2012

Primary endpoint
15 August 2018

15 August 2018

Quick facts

Lead sponsor	University Hospital, Basel, Switzerland
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	29 August 2012
Primary completion	15 August 2018
Estimated completion	15 August 2018
Sites	1 location across Switzerland

Drugs / interventions tested

Tissue engineered cartilage graft — full drug profile →

Conditions studied

Cartilage Lesion — all drugs for Cartilage Lesion →
Degenerative Lesion of Articular Cartilage of Knee — all drugs for Degenerative Lesion of Articular Cartilage of Knee →

Sponsor

University Hospital, Basel, Switzerland

Who can join

Adults 18 to 55, any sex, with Cartilage Lesion or Degenerative Lesion of Articular Cartilage of Knee. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate the safety and feasibility of implanting an engineered cartilage graft obtained by culturing expanded autologous nasal chondrocytes within a collagen type I/III membrane into the cartilage defect on the femoral condyle and/or trochlea of the knee after a traumatic injury.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Scaffolding Strategies for Tissue Engineering and Regenerative Medicine Applications.
Pina S, Ribeiro VP, Marques CF, Maia FR, et al · · 2019 · cited 248× · PMID 31195642 · DOI 10.3390/ma12111824
Nasal chondrocyte-based engineered autologous cartilage tissue for repair of articular cartilage defects: an observational first-in-human trial.
Mumme M, Barbero A, Miot S, Wixmerten A, et al · · 2016 · cited 166× · PMID 27789021 · DOI 10.1016/s0140-6736(16)31658-0
Engineering Stem and Stromal Cell Therapies for Musculoskeletal Tissue Repair.
Loebel C, Burdick JA. · · 2018 · cited 105× · PMID 29429944 · DOI 10.1016/j.stem.2018.01.014
The Current Status of Clinical Trials on Biologics for Cartilage Repair and Osteoarthritis Treatment: An Analysis of ClinicalTrials.gov Data.
Zhang Z, Schon L. · · 2022 · cited 21× · PMID 35546280 · DOI 10.1177/19476035221093065
Intra-individual comparison of human nasal chondrocytes and debrided knee chondrocytes: Relevance for engineering autologous cartilage grafts.
Lehoczky G, Wolf F, Mumme M, Gehmert S, et al · · 2020 · cited 15× · PMID 31743993 · DOI 10.3233/ch-199236
Bone-forming capacity of adult human nasal chondrocytes.
Pippenger BE, Ventura M, Pelttari K, Feliciano S, et al · · 2015 · cited 15× · PMID 25689393 · DOI 10.1111/jcmm.12526
Advanced Therapy medicinal products for autologous chondrocytes and comparison of regulatory systems in target countries.
Kim J, Park J, Song SY, Kim E. · · 2022 · cited 14× · PMID 35582708 · DOI 10.1016/j.reth.2022.04.004
Biomarker Signatures of Quality for Engineering Nasal Chondrocyte-Derived Cartilage.
Asnaghi MA, Power L, Barbero A, Haug M, et al · · 2020 · cited 14× · PMID 32318561 · DOI 10.3389/fbioe.2020.00283

Verify or expand the search:

Other recruiting trials for Cartilage Lesion

Currently open trials in the same condition.

NCT06932380 — A Talus Implant in Patients Between 20-60 Years of Age Followed up for a Minimum of 2 Years After Surgery · NA · recruiting

Other University Hospital, Basel, Switzerland trials

Trials by the same sponsor.

NCT07444788 — Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants · Phase 1 · recruiting
NCT07494214 — Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants · Phase 1 · recruiting
NCT07419048 — Artificial Intelligence or Human Hand? Evaluating Inferior Vena Cava Imaging for Hydration Status · recruiting
NCT06978777 — Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity · NA · recruiting
NCT07273630 — Effect of Protein Supplementation and Fluid Restriction on Plasma Sodium Levels in Patients Undergoing Pituitary Surgery · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01605201 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Basel, Switzerland
Last refreshed: 27 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01605201.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing